Daily Stock Analysis, ATNM, Actinium Pharmaceuticals Inc, priceseries

Actinium Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.69
Close
0.63
High
0.71
Low
0.63
Previous Close
0.67
Daily Price Gain
-0.04
YTD High
0.78
YTD High Date
Jan 25, 2018
YTD Low
0.33
YTD Low Date
Apr 25, 2018
YTD Price Change
-0.02
YTD Gain
-3.09%
52 Week High
1.33
52 Week High Date
Jun 29, 2017
52 Week Low
0.33
52 Week Low Date
Apr 25, 2018
52 Week Price Change
-0.60
52 Week Gain
-48.79%
Company Information
Stock Symbol
ATNM
Exchange
NYSE MKT
Company URL
http://www.actiniumpharmaceuticals.com
Company Phone
646-677-3875
CEO
Kaushik J. Dave
Headquarters
New York
Business Address
275 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001388320
About

Actinium Pharmaceuticals, Inc. operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers. It targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company was founded in 1993 and is headquartered in New York, NY.

Description

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.